Highest-materiality recent filing
Lucid Diagnostics Q1 2026: Processed 3,177 EsoGuard tests, revenue $1.3M, net loss $23.6M
Processed 3,177 EsoGuard tests in Q1, generating $1.3M in revenue; operating expenses $13.4M including $1.4M stock comp.
Lucid Diagnostics closes $18M underwritten offering of 18M shares at $1.00/share
Closed sale of 18,000,000 shares at $1.00/share; gross proceeds $18M, net proceeds ~$16.8M.
Lucid Diagnostics prices $18M underwritten offering of 18M shares at $1.00 per share
Offering of 18,000,000 common shares at $1.00 each; gross proceeds ~$18M.
Lucid Diagnostics Q4 2025 revenue $1.5M, net loss $16.3M; VA contract awarded
Q4 EsoGuard tests 3,664; revenue $1.5M; GAAP net loss $16.3M ($0.12/share); non-GAAP adj. loss $12.6M ($0.10/share).
Processed 2,841 EsoGuard tests in Q3 2025, revenue $1.2 million.
Lucid Diagnostics closes $28.75M public offering of 28.75M shares at $1.00/share
Closed underwritten public offering of 28,750,000 shares at $1.00 per share, including full exercise of underwriters' option for 3,750,000 additional shares.
Lucid Diagnostics prices $25M public offering of 25M shares at $1.00 per share
Priced 25,000,000 shares of common stock at $1.00 per share; gross proceeds ~$25M before expenses.
Lucid Diagnostics Q2 2025 revenue $1.2M; net loss $7.9M; cash $31.1M after offering
Processed 2,756 EsoGuard tests in Q2 2025; revenue $1.2 million.
Lucid Diagnostics enters $25M ATM equity offering with Maxim Group
Up to $25M of common stock may be sold at-the-market via Maxim Group as agent.
Lucid Diagnostics Q1 2025 revenue $0.8M, net loss $36M; raises ~$46.7M in equity
Revenue of $0.8M from 3,034 EsoGuard tests; GAAP net loss $36.0M ($0.52/share); adjusted loss $11.2M ($0.16/share).
Lucid Diagnostics prices $15M public offering of 12.5M shares at $1.20 per share
Gross proceeds ~$15M from 12.5M shares at $1.20; underwriters have 45-day option for 1.875M additional shares.
Lucid Diagnostics reports Q4 EsoGuard revenue $1.2M, record 4,042 tests processed
Record 4,042 EsoGuard tests processed in Q4 2024, up 45% sequentially and 84% year-over-year.
Lucid Diagnostics closes $15.3M registered direct offering of 13.9M shares at $1.10/share
Closed offering of 13,939,331 common shares at $1.10 per share for gross proceeds of $15.3M.
Lucid Diagnostics raises $15.3M in registered direct offering of 13.9M shares at $1.10/share
Gross proceeds of ~$15.3M from sale of 13,939,331 shares at $1.10/share; net proceeds ~$14.5M after fees/expenses.
Sold $21.95M principal amount Senior Secured Convertible Notes, net proceeds $18.3M after repaying 2023 note.
Lucid Diagnostics sells $21.75M in convertible notes to redeem existing 2023 note
Aggregate $21.75M in Senior Secured Convertible Notes sold to accredited investors.
EsoGuard revenue $1.2M, up 20% sequentially from Q2 2024 and 50% YoY from Q3 2023.
Lucid Diagnostics redeems 2023 convertible note, issues $1.00/sh 12% secured notes due 2029
Notice to redeem 2023 Senior Convertible Note at optional redemption price; payment due within 10-20 business days.
Lucid Diagnostics Q2 2024: EsoGuard test volume +31% QoQ to record 3,147; revenue $1.0M
EsoGuard volume 3,147 (record), up 31% sequentially and 44% YoY; revenue $1.0M flat QoQ but +514% YoY.
Lucid Diagnostics receives Nasdaq bid price deficiency notice; 180 days to regain compliance
Received Nasdaq notice on June 21, 2024: closing bid price below $1 for 30 consecutive business days.
Lucid Diagnostics Q1 revenue $1.0M; net loss $18.1M; EsoGuard volume up 10% sequentially
EsoGuard revenue $1.0M, flat vs Q4'23 but up 124% YoY.
Lucid Diagnostics closes $11.6M Series B-1 preferred offering; appoints Dennis Matheis to board
Gross proceeds from combined Series B / B-1 offering total $29.8M; $11.6M from Series B-1, $18.6M from prior Series B.
Lucid Diagnostics announces positive NCI study: EsoGuard detects 89% of short-segment precancers
EsoGuard showed 89% sensitivity for short-segment Barrett's esophagus (SSBE) in NCI-sponsored multicenter study.
Lucid Diagnostics completes $18.16M Series B Preferred offering and exchange of Series A/A-1 shares
Gross proceeds of $18.16M: $12.495M from new subscriptions and $5.67M from Series A-1 sales immediately exchanged.
Effective May 6, 2024, the board of directors of the Company appointed Dennis Matheis as a Class A director of the Company.
Max materiality 0.80 · Median 0.65 · Most common event other_material